We discussed IPOs amidst Anthropic’s upcoming debut in our most recent issue of Priced to Compound, highlighting the impact of dilution on a companies first year of trading.
For Anthropic, we have mapped out the their unlock schedule. As you might expect, only a fraction of supply will be available for trading during its first week. Unlocks will accelerate into next year before tapering off as the company reaches a full year of public market trading.
Our share count does not include further dilution that may come after IPO from acquisitions or additional equity raises.
Nvidia earnings are shaping up to be one of the most consequential reports of the year as the company grasps with Jensen Huang’s departure.
The stock is tracking its worst performance heading into earnings in more than 20 years. Does the stock find relief after earnings or continue to struggle?
Disclosure: We own Nvidia (NVDA). Not investment advice.
23
Defensive sectors since the midterms:
Staples: +3.8%
Health care: +2.6%
Real Estate: +1.6%
Utilities: +1.4%
Energy: -2.6%
Read the latest on midterm rotations in our latest issue:
open.substack.com/pub/priced…
3
Midterms accelerated volatility last week as markets adjust to a new political backdrop. With Anthropic’s highly touted IPO expected next week, can the market find its footing?
We take a look at Anthropic’s S-1, historical IPO returns and much more in our November Issue of Priced to Compound.
Read the full report on pricedtocompound.com
Our November issue of Priced to Compound drops tomorrow👇
pricedtocompound.com
October Issue drops tomorrow for subscribers!
This issue features market commentary, a new portfolio position, and further buys on existing positions.
Subscribe @ pricedtocompound.com to receive in your inbox tomorrow.
$META Meta is up 30% in September through Wednesday. In fourteen years as a public company only July 2013 (+48%) and November 2012 (+33%) were bigger months.
Since Friday's close it has added about $200 billion of market value.
Where has Sprouts' revenue growth come from? We estimate ~44% of it has come from private label since fiscal 2019.
Revenue grew from $5.63B in fiscal 2019 to $8.81B in fiscal 2025. Private label's share went from approximately 14% to just over 25% over the same period, per the company's 10-Ks. With total sales and the private label share both rising, we estimate private label sales have grown at a CAGR of roughly 18–19% from fiscal 2019 to fiscal 2025.
Fiscal 2019
Revenue: $5.63B
Private label share: ~14%
Estimated private label sales: ~$790M
Fiscal 2025
Revenue: $8.81B
Private label share: ~25%
Estimated private label sales: ~$2.2B
Change
Revenue: +$3.18B
Estimated private label sales: +$1.41B (~44% of the increase) $SFM
Nineteen years. That is how long it has been since the 10-year Treasury last closed at or above 5%. September 15th, 2026 marks the first time since July 19th, 2007.
With rates continuing to rise, does the Fed hold or hike today?
Healthcare is seeing dispersion within its sector: biotech is up 29% (XBI), pharmaceuticals is up 20% and the healthcare sector fund XLV is up 8%, while medical devices are down 17% (IHI).
Medical Devices (IHI) is feeling pressure from its largest holdings: Abbott Laboratories (ABT), Intuitive Surgical (ISRG) and Stryker (SYK), representing 42% of the fund, are all down at least 15% year to date.
1
91
Broken business or a FCF love story? Match Group free cash flow reaches record levels even as revenue flattens. $MTCH
Read more about Match Group in the full issue: open.substack.com/pub/priced…
16
On September 1st, Sprouts announced CEO Jack Sinclair will be transitioning to Executive Chairman. During his tenure as CEO, he has increased Sprouts store footprint by 150, a 44% increase, while also more than doubling net margin. COO Nick Konat will take over as CEO $SFM
Read more about Sprouts in our latest issue: open.substack.com/pub/priced…
23
Each equity covered in our monthly issue gets a company tear-sheet and thesis page. The tear-sheet includes high-level information such as:
- Company overview and competitors
- Key stock data
- Capital structure
- Up to 10 years of financials
- A snapshot of our thesis
1
1
50
Each tear-sheet is followed by a thesis page that dives into key drivers, valuation and risks.
Our first issue is free and open to all, but follow-on issues will require our subscription, starting at $20/mo or $200/yr.
Read the full issue: pricedtocompound.com/p/price…
25














